Free Trial
NASDAQ:ENTA

Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis

Enanta Pharmaceuticals logo
$7.89 -0.08 (-1.00%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)

Key Stats

Today's Range
$7.73
$8.03
50-Day Range
$5.05
$7.97
52-Week Range
$4.09
$17.24
Volume
78,004 shs
Average Volume
282,965 shs
Market Capitalization
$168.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Moderate Buy

Company Overview

Enanta Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

ENTA MarketRank™: 

Enanta Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 556th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Enanta Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Enanta Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Enanta Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($4.65) to ($4.98) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Enanta Pharmaceuticals is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Enanta Pharmaceuticals is -1.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Enanta Pharmaceuticals has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Enanta Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    12.59% of the float of Enanta Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Enanta Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Enanta Pharmaceuticals has recently decreased by 8.09%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Enanta Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Enanta Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.59% of the float of Enanta Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Enanta Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Enanta Pharmaceuticals has recently decreased by 8.09%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Enanta Pharmaceuticals has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    Only 2 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.89% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Enanta Pharmaceuticals' insider trading history.
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Stock News Headlines

Enanta Pharmaceuticals, Inc. (ENTA) - Yahoo Finance
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Headlines

ENTA Stock Analysis - Frequently Asked Questions

Enanta Pharmaceuticals' stock was trading at $5.75 at the beginning of the year. Since then, ENTA shares have increased by 37.2% and is now trading at $7.89.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its quarterly earnings results on Monday, May, 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($1.04) by $0.02. The biotechnology company had revenue of $14.93 million for the quarter, compared to the consensus estimate of $15.96 million. Enanta Pharmaceuticals had a negative net margin of 149.57% and a negative trailing twelve-month return on equity of 79.83%.

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/12/2025
Today
7/04/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENTA
Employees
160
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$24.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+128.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$116.04 million
Net Margins
-149.57%
Pretax Margin
-153.41%

Debt

Sales & Book Value

Annual Sales
$67.64 million
Price / Cash Flow
N/A
Book Value
$6.08 per share
Price / Book
1.30

Miscellaneous

Free Float
18,408,000
Market Cap
$168.69 million
Optionable
Optionable
Beta
0.84

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ENTA) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners